Skip to main content
James Blachly, MD, Hematology, Columbus, OH

JamesStewartBlachlyMD

Hematology Columbus, OH

Hematologic Oncology, Myeloproliferative Disorder Hematology-Oncology

Tenured Associate Professor of Medicine. Leader of OSU Hereditary Hematologic Neoplasm Program and HALT Clinic Co-Director. Director of Sequencing at OSU Experimental Hematology Lab. Co-Chair of Alliance A-STOR.

Dr. Blachly is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
  • Connect with colleagues in the same hospital or clinic.
  • Read the latest clinical news, personalized to your specialty.

See Dr. Blachly's full profile

Already have an account?

  • Office

    460 W 10th Ave
    1st Floor
    Columbus, OH 43210
    Fax+1 614-293-6050

Education & Training

  • Ohio State University Hospital
    Ohio State University HospitalFellowship, Hematology and Medical Oncology, 2011 - 2014
  • University of Arkansas for Medical Sciences (UAMS) College of Medicine
    University of Arkansas for Medical Sciences (UAMS) College of MedicineResidency, Internal Medicine, 2007 - 2011
  • University of Arkansas For Medical Sciences College of Medicine
    University of Arkansas For Medical Sciences College of MedicineClass of 2007

Certifications & Licensure

  • OH State Medical License
    OH State Medical License 2011 - 2025
  • AR State Medical License
    AR State Medical License 2010 - 2023

Clinical Trials

Publications & Presentations

PubMed

Journal Articles

  • NF1 Mutations Are Recurrent in Adult Acute Myeloid Leukemia and Confer Poor Outcome  
    Eunice S Wang, Bayard L Powell, Richard M Stone, John C Byrd, Clara D Bloomfield, Alice Mims, Andrew J Carroll, Jonathan E Kolitz, James S Blachly, Nature

Abstracts/Posters

  • The Protein Kinase C Inhibitor MS-553 for the Treatment of Chronic Lymphocytic Leukemia
    James S. Blachly, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
  • Rapid Molecular Diagnostics for Acute Myeloid Leukemia Using Single-Molecule Sequencing
    James S. Blachly, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
  • NPM1 mutations Using Deep Amplicon Sequencing and Broad Next Generation Sequencing at the Time of Complete Remission Is Informative to Predicting Risk of Relapse Follo...
    James S. Blachly, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
  • Join now to see all

Lectures

  • Infection at the Time of Initial Therapy for Hairy Cell Leukemia Is Associated with Inferior Time to Next Treatment 
    2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
  • A Precision Medicine Heirarchical Classification Developed Using Variant Allele Frequency (VAF) for Treatment of Older Patients (Pts) with Acute Myeloid Leukemia (AML)... 
    2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
  • Clinical and Molecular Characteristics of Acute Myeloid Leukemia (AML) Patients with TP53 Mutations and TP73 Mutations 
    2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
  • Join now to see all

Press Mentions

  • Editorial Roundup: Pennsylvania
    Editorial Roundup: PennsylvaniaAugust 21st, 2021
  • NCCN Annual Conference Sheds Light on Treatment Disparities, Significance of the Doctor-Patient Relationship, Supportive Care Issues, and the Latest Guidelines Updates
    NCCN Annual Conference Sheds Light on Treatment Disparities, Significance of the Doctor-Patient Relationship, Supportive Care Issues, and the Latest Guidelines UpdatesMarch 29th, 2017